Natural Molecular Testing
Currently in Chapter 11, Natural Molecular Testing Will Shut Down, Repay CMS $71M
As part of the settlement reached with the agency, NMT will also cease all operations, end its plans to reorganize, and liquidate its assets.
GenMark Diagnostics CEO Hany Massarany elaborated recently on the company's plans for its automated NexGen system and its associated test menu, as well as GenMark's efforts to reach European customers.
Luminex hit a number of "unexpected speed bumps" in the third quarter that caused the company to miss both its internal and Wall Street's projections, and to lower its 2013 revenue guidance.
Natural Molecular Testing created a stir in the marketplace last week when it announced it would be converting its pharmacogenetic test services to a new panel based on Luminex's xMAP multiplex bead array technology.
GenMark Lowers Revenue Guidance after NMT, Luminex Deal
NEW YORK (GenomeWeb News) – GenMark Diagnostics said after the close of the market Monday that it has lowered its annual revenue guidance to approximately $30 million from its previous expectation of $35 million.